We are live on ! Find out more
STIM icon

Neuronetics

74 hedge funds and large institutions have $383M invested in Neuronetics in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 21 increasing their positions, 20 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more capital invested

Capital invested by funds: $287M → $383M (+$96.4M)

33% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 18

27.42% more ownership

Funds ownership: 41.71%69.13% (+27%)

9% more funds holding

Funds holding: 6874 (+6)

5% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 20

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

Holders
74
Holders Change
+6
Holders Change %
+8.82%
% of All Funds
1.69%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
24
Increased
21
Reduced
20
Closed
18
Calls
Puts
Net Calls
Net Calls Change

STIM Hedge Fund Activity: Q3 2018 in Review

74 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Neuronetics (STIM) for Q3 2018, worth a combined $383M — up 34% from $287M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new STIM positions and 18 closed out — a net gain of 6 holders — while 21 added to existing stakes and 20 trimmed.

The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $16M. The largest seller was Peregrine Capital Management, exiting entirely with an estimated $4.66M sold.

  • 74 institutional investors held Neuronetics (STIM) as of Q3 2018, up from 68 in Q2 2018.
  • Funds reported $383M of Neuronetics stock for Q3 2018, up 34% quarter-over-quarter.
  • 24 funds opened new Neuronetics positions in Q3 2018 and 18 closed out, a net change of +6 holders.
  • The largest Neuronetics buyer in Q3 2018 was Novo Holdings A/S, an estimated $16M added.
  • The largest Neuronetics seller in Q3 2018 was Peregrine Capital Management, an estimated $4.66M sold.

Based on aggregated 13F filings for Q3 2018.